AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05205928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy
Description: The blinded drug will be used with participant's routine therapy (+ continuous glucose monitoring if not already in use) for 11 weeks with follow-up from qualified research personnel concerning pump settings, side effects, and incremental dose increase. While continuing to use the medication, there are 4 weeks of closed-loop pump therapy and drug use; glycemic outcomes will be taken from the last 4 weeks. This will be followed by laboratory and anthropometric testing, followed by 2 weeks of wash-out.
Study NCT05781243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer Solution
Description: Patients in the LR (Lactated Ringer solution) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
Study NCT05781243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Patients in the NS (Normal Saline) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
Study NCT05399992 — intervention group
Intervention type: OTHER
Intervention: Inclisiran
Description: Prospective observational study. There is no treatment allocation. Patients who are receiving or intend to receive inclisiran are eligible to enroll into this study.
Study NCT05264714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: 150 mg oral disintegrating tablet every other day for one week
Study NCT06002789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
Description: For MSI-H/MSS (dMMR/pMMR) mixed sMPCC, a combination of neoadjuvant chemotherapy with mFOLFOX6 and immunotherapy with PD-1 monoclonal antibody are applied.
Study NCT06002789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
Description: For all-MSI-H (dMMR) sMPCC, single-drug PD-1 monoclonal antibody immunotherapy is applied.
Study NCT06188936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExSeed®
Description: In work package 3, participants will use the provided ExSeed® device and associated app downloaded onto their smartphone to analyse a semen sample provided at home. The app gives a result of normal or below normal, as well as an exact value for sperm concentration, progressive motility, and total motile sperm count. The patient will send their semen analysis results from the smartphone to the research team via secure email.
Study NCT06188936 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Survey
Description: Surveys will be completed on a hard copy or electronically.
Study NCT04774068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Given PO
Study NCT04774068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Given IV
Study NCT06504446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOC-110
Description: Inhalation powder
Study NCT06504446 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation powder
Study NCT05557409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05
Description: AXS-05 tablets, taken twice daily
Study NCT05557409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, taken twice daily
Study NCT06074666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CareMeds Intervention
Description: 3 parenting sessions will be offered during weeks 2 through 4 of the study period.
Study NCT06074666 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: 3 parenting sessions will be offered during weeks 13 through 15 of the study period.
Study NCT06199726 — intervention group
Intervention type: BEHAVIORAL
Intervention: REFLECT web-based tool
Description: Partnering with Nest Genomics, Investigators have developed a customizable web-based tool to support AYA patients through their cancer diagnosis journey for topics related to future family building and genetics. This interactive tool will include educational content to organize knowledge, make connections between concepts, and will include web links to more in-depth content and embedded videos. The interface will allow users to document questions that would be helpful in provider discussions and include decision support to assist with determining values and needs for proceeding with consultations related to genetic counseling and testing, and fertility.
Study NCT06472973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-transplant addiction intervention
Description: The first addiction consultation will be conducted using the BRENDA method which allows the addiction specialist to carry out a psychosocial assessment, to entrust the results of this assessment to the participant, to answer their questions and to evaluate their reactions. Risk factors for alcohol relapse will be collected: social determinants, male gender, psychiatric comorbidities, duration of alcohol abstinence before LT(≥ or \< 6 months) and young age (\< 40 years). If the addiction specialist notes the presence of at least 3 risk factors for alcohol relapse, targeted addiction follow-up will be proposed to the participant including outpatient consultations with motivational interview at least every 4 weeks +/- pharmacological treatment of alcohol use disorder.In case of alcohol relapse or a period of high vulnerability to relapse, specific hospitalizations can be scheduled. If the participant has \<3 risk factors, an addictology consultation every 6 months at most will be proposed.
Study NCT06219941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0901
Description: Antibody-drug conjugate/Biologic
Study NCT06007495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational full-face mask with expiratory washout
Description: With cross-over in randomized order, mask worn for 30 minutes with prescribed single-limb non-invasive ventilation
Study NCT06007495 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional full-face mask - single-limb
Description: With cross-over in randomized order, conventional mask such as RT077, worn for 30 minutes with prescribed single-limb non-invasive ventilation
Study NCT06007495 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional full-face mask - dual-limb
Description: With cross-over in randomized order, conventional mask such as RT076, worn for 30 minutes with prescribed dual-limb non-invasive ventilation
Study NCT05212584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7CAR T cells
Description: CD7 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
Study NCT05341050 — intervention group
Intervention type: DRUG
Intervention: TKI
Description: halve dose of 2G-TKI for 12 months and then withdrawal for 12 months
Study NCT06219941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Chemotherapy agents
Study NCT06219941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Chemotherapy agents
Study NCT06219941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l-leucovorin
Description: Chemotherapy agents
Study NCT06219941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Chemotherapy agents
Study NCT06219941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal Irinotecan
Description: Chemotherapy agents
Study NCT06219941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy agents
Study NCT06388200 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Sub-Retinal Administration of OCU400-301
Description: Sub-Retinal Administration of OCU400-301
Study NCT04301089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pico G2 4K Headset with Applied VR software
Description: headset worn at time points defined in study
Study NCT04879706 — intervention group
Intervention type: OTHER
Intervention: None planned
Description: No intervention planned
Study NCT06407492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leech
Description: The leeches used in the treatment were obtained from people producing in culture media. Leech therapy was applied to the patients once a week. Before coming to treatment, patients were warned not to use perfume or apply any chemicals on the skin. While no skin preparation was made before the treatment, in patients with cold legs, the area where the leech would be applied was heated to ensure easy adhesion of the leech. The leeches left on their own after approximately 40 to 38 minutes, but the leeches that did not release on their own until 60 minutes were removed by scraping them from the skin with the help of a gauze. The leeches used in the treatment were used only once and the used ones were disposed of by throwing them into medical waste bags. After the leeches were removed from the patient, the wound was covered with a printed bandage. Patients were instructed to remove the bandage after 10-12 hours.
Study NCT06407492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: Conventional physiotherapy applications were performed. Physiotherapy applications were performed with transcutaneous electrical nerve stimulation, hotpack and ultrasound.
Study NCT05719870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational training
Description: The intervention will include: first, educational training of patients/caregivers at hospital discharge by a multidisciplinary team; second, after hospital discharge, a phone recall on the prescribed therapies and a one-week phone consultant service managed by a geriatrician, supported by the multidisciplinary team, to address potential concerns on prescribed treatments.
Study NCT04882293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose
Description: 1 tablet once a day, 20 mg /160 mg, Orally
Study NCT04882293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin (Lipitor ®)
Description: 1 tablet once a day, 20 mg, Orally
Study NCT05265182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: Create an immersive technology system for managing the behavioral and psychological symptoms of dementia and determine its acceptability, usability, and safety in the healthy adult population initially, using semi-Cave or head-mounted display.
Study NCT06407492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Conventional physiotherapy applications were performed. Physiotherapy applications were performed with transcutaneous electrical nerve stimulation, hotpack and ultrasound.
Study NCT06407492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: In this taping technique, skin color, 5cmX5m kinesio tape material was used. Again, the patient standing upright will be prepared in terms of clothing and skin. The standing patient will then be asked to lean forward. Taping will be done using a special muscle technique for this group. When applying tape to the right paravertebral region, first the lower end of the tape will be adhered 7 cm below the sacroiliac joint, at the level of the paravertebral muscles. When applying tape to the left paravertebral region, the same procedure will be done in reverse as on the right, and the tape will not be stretched at all. The third tape will be applied to the patient who is standing upright and bending slightly forward, passing over the sacroiliac joints and parallel to the ground, with the tape stretched by 25%.
Study NCT05339815 — intervention group
Intervention type: DEVICE
Intervention: SMR shoulder arthroplasty
Description: Data collection of population that underwent a reverse shoulder arthroplasty performed with SMR 36-mm CoCrMo versus 40-mm cross-linked UHMWPE glenospheres
Study NCT06476704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of L-TC
Description: Administration of L-TC (300 mg) as an IV perfusion, daily before each radiotion session
Study NCT06476704 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HFRT alone
Description: HFRT : 30 Gy in 5 fractions of 6 Gy.~1 fraction per day, 5 days per week.
Study NCT05050305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marizomib
Description: Intravenous Infusion
Study NCT05050305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Taken orally
Study NCT05050305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Taken orally
Study NCT05686460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ice massage
Description: After the students who met the sample selection criteria applied Student Information Form. On the first day of the participating students' menstruation, prior to the application (when the pain started), the Visual Analogue Scale (VAS), General Comfort Questionnaire (GCQ) and Dysmenorrhea Follow-up Form were filled in at the pre-test. The Hegu point of the participating students was detected with the acupuncture point finder. Ice cubes whose dimensions were 2x2x2 cm were wrapped with gauze and placed in a plastic bag. Vaseline® jelly was spread on the application area. The application applied 2 minutes of ice massage 7 times at 15-second intervals. The participants' pain levels were assessed three times, as soon as the application was over, 30 and 60 minutes after the application (Post-test).~On the second day of menstruation, the participants were asked to fill in the VAS, GCQ, and Effects of Dysmenorrhea Scale (EDS).
Study NCT05686460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music medicine
Description: After the students who met the sample selection criteria applied Student Information Form. On the first day of the participating students' menstruation, prior to the application (when the pain started), the Visual Analogue Scale (VAS), General Comfort Questionnaire (GCQ) and Dysmenorrhea Follow-up Form were filled in at the pre-test. Depending on their preference, each participant wearing personalized headphones was played instrumental music in the pre-menstruation period for 30 minutes. The volume of the music was adjusted based on the verbal feedback or facial expressions of the students. The participants' pain levels were assessed three times, as soon as the application was over, 30 and 60 minutes after the application (Post-test). On the second day of menstruation, the participants were asked to fill in the VAS, GCQ, and Effects of Dysmenorrhea Scale (EDS).
Study NCT06274619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV A Memphis 37
Description: RSV A Memphis 37 challenge agent
Study NCT06172738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the left atrial appendage closure through surgery.
Description: Surgical closure of the left atrial appendage during the set of an elective open heart surgery with the inclusion criteria fulfilled.
Study NCT06494501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Subjects will be administered a single subcutaneous injection of 284 mg inclisiran for injection at predefined time points.
Study NCT06548503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Si.Pi.Mi product
Description: Assumption of the product as detailed in the protocol
Study NCT06548503 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Assumption of placebo
Study NCT04750473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan
Study NCT04656301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: A single dose of psilocybin 25 mg will be administered orally in the Biological Studies Unit of New York State Psychiatric Institute
Study NCT06501807 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Biologic treatments available in Chronic Rhinosinusitis with Nasal Polyps (dupilumab, mepolizumab and benralizumab according to their marketing approval).
Description: Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks).
Study NCT04750473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV
Study NCT05035745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Patients will be treated with Talazoparib daily on a 4 weekly cycle (28 days)
Study NCT05035745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Patients will be treated with Selinexor once per week (3 out of 4 weeks), on a 4 weekly cycle (28 days)
Study NCT04750473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV
Study NCT04750473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study NCT03959046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GIST
Description: The GIST intervention will train physicians in an alternative way of communicating with their patients.
Study NCT05118035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-enabled ECG-based Screening Tool
Description: Primary care clinicians in the intervention group had access to the report, which shows the risk prediction results for each patients. Moreover, the clinicians will recieve a short message when patients with a high risk ECG identified by AI.
Study NCT05665530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT2527
Description: PRT2527 will be administered by intravenous infusion once weekly.
Study NCT05665530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib will be provided in capsules for oral administration once or twice daily.
Study NCT05665530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be provided in tablet for oral administration once daily
Study NCT04887350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Student-Senior Isolation Prevention Partnership (SSIPP)
Description: The Student-Senior Isolation Prevention Partnership partners medical students with older adults in the community to provide social support and connection through regular phone calls. The goal of SSIPP is to reduce rates of anxiety, depression, and loneliness, while fostering resilience among seniors in our communities. This intervention will be delivered by phone to study participants once a week for a 30-60 minute session over a 12-week period.
Study NCT04887350 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Student-Senior Isolation Prevention Partnership (SSIPP)
Description: The Student-Senior Isolation Prevention Partnership partners medical students with older adults in the community to provide social support and connection through regular phone calls. The goal of SSIPP is to reduce rates of anxiety, depression, and loneliness, while fostering resilience among seniors in our communities. This intervention will be delivered by phone to study participants once a week for a 30-60 minute session over a 12-week period.
Study NCT04451044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips SyncVision system with Philips pressure wires
Description: Intent to use physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy
Study NCT04451044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard of care angiographically-guided PCI
Description: Intent to use PCI standard of care angiographically-guided PCI for determining the PCI strategy
Study NCT04887350 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Therapy (PST).
Description: Problem Solving Therapy is a psychotherapeutic intervention that teaches community members to identify and clarify problems at hand, set clear, achievable goals, brain-storm solutions to the problem, select their preferred solution, implement this solution, and evaluate the outcomes. This intervention will be delivered by a trained healthcare professional by phone to study participants once a week for a 30-60 minute session over a 12-week period.
Study NCT04887350 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Problem Solving Therapy (PST).
Description: Problem Solving Therapy is a psychotherapeutic intervention that teaches community members to identify and clarify problems at hand, set clear, achievable goals, brain-storm solutions to the problem, select their preferred solution, implement this solution, and evaluate the outcomes. This intervention will be delivered by a trained healthcare professional by phone to study participants once a week for a 30-60 minute session over a 12-week period.
Study NCT05978219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine Tablets
Description: Mirtazapine tablet form, orally, once or twice daily, 15-45 mg
Study NCT06077162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Nutrition Education Classes
Description: Diabetes nutrition education offered by registered dietitian in group-based classes.
Study NCT06077162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Food Security Resource
Description: Participants offered security resource which is a $30.00 Aldi (grocery store) gift card provided weekly for 12 weeks.